Macquarie Group
EIGR

Macquarie Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Macquarie Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-23
Closed -$10K – 2417
2017
Q4 		$10K Buy
+23
New +$8.22K ﹤0.01% 2265

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group's EIGR Position: Q1 2018 in Review

Macquarie Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2018, closing a stake of 23 shares — an estimated $10K sold.

Macquarie Group first reported a position in EIGR in Q4 2017 and held it in 1 quarter. The position peaked at $10K in Q4 2017. 39 funds tracked by Wall St. Rank hold EIGR as of Q1 2018.

  • Macquarie Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 23 Eiger BioPharmaceuticals, Inc. shares in Q1 2018, an estimated $10K.
  • Macquarie Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Eiger BioPharmaceuticals, Inc. position peaked at $10K in Q4 2017.
  • 39 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.